Case series of light chain systemic amyloidosis in a high complexity hospital in Medellín

Serie de casos de amiloidosis sistémica de cadenas ligeras en un hospital de alta complejidad en Medellín

Main Article Content

Kenny Mauricio Gálvez Cárdenas
Maria Clara Escobar Millán
Juan Felipe Morantes Rubiano
Abstract

Amyloidosis is a group of rare diseases characterized by the abnormal deposit of proteins in the tissues. It can affect any organ except the central nervous system and have a heterogeneous clinical presentation depending on the damage to the involved organ. Methods: We present a descriptive, retrospective case series study of 11 patients with a confirmed diagnosis of light chain amyloidosis in a highly complexity institution in Medellín. The objective was to describe the clinical, paraclinical, and imaging presentation of patients, during a period between 2014 and 2020. A collection of demographic and clinical data from medical records was carried out, to later compare them with data from the literature. Results: A total of 11 patients were found, in which cardiac and renal involvement were the most common. The main symptoms reported were edema in the extremities, asthenia, adynamia, weight loss and dyspnea. The organs where the amyloid deposit was identified by histopathology were bone marrow, gastrointestinal tract, kidney, lung and skin. In the electrocardiogram the two main findings were a pattern of low voltage and pseudoinfarction. Left ventricular hypertrophy and pericardial effusion were common echocardiographic findings. Conclusion: the most frequent type of monoclonal gammopathy in the series was due to lambda light chains.

Keywords

Downloads

Download data is not yet available.

Article Details

Author Biographies (SEE)

Kenny Mauricio Gálvez Cárdenas, Hospital Pablo Tobón Uribe, Medellín, Colombia.

Médico Internista, Hematólogo del Hospital Pablo Tobón Uribe, Medellín, Colombia.

Maria Clara Escobar Millán, Universidad CES, Medellín, Colombia.

Médica general Universidad CES, Medellín, Colombia.

Juan Felipe Morantes Rubiano, Universidad Pontificia Bolivariana, Medellín, Colombia.

Médico residente de Medicina Interna Universidad Pontificia Bolivariana, Medellín, Colombia.

References

Fontana M, Ćorović A, Scully P, Moon JC. Myocardial Amyloidosis: The Exemplar Interstitial Disease [Internet]. JACC. Cardiovascular imaging. 2019. Disponible en: https://doi.org/10.1016/j.jcmg.2019.06.023

Manolis AS, Manolis AA, Manolis TA, Melita H. Cardiac amyloidosis: An underdiagnosed/underappreciated disease [Internet]. European Journal of Internal Medicine. 2019;67:1–13. Disponible en: https://doi.org/10.1016/j.ejim.2019.07.022

Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020 [Internet]. Blood. 2020136(23):2620–7. Disponible en: https://doi.org/10.1182/blood.2020006913

Gertz MA. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment [Internet]. American Journal of Hematology. 2022;97(6):818–29. Disponible en: https://doi.org/10.1002/ajh.26569

Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau JL, Mohty M. Comprehensive Review of AL amyloidosis: some practical recommendations [Internet]. Blood Cancer Journal. 2021;11(5):97. Disponible en: https://doi.org/10.1038/s41408-021-00486-4

Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes [Internet]. Journal of Clinical Oncology. Wolters Kluwer; 2012; 30(36):4541–9.Disponible en: https://doi.org/10.1200/JCO.2011.37.7614

Lacouture-Fierro JA, Mejía-Buriticá L, Ribero-Vargas DA. Amiloidosis AL: conceptos actuales [Internet]. Medicina y Laboratorio. 2022;26(2):119–39. Disponible en: https://doi.org/10.36384/01232576.572

Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis [Internet]. The Lancet. Elsevier; 2016;387(10038):2641–54. Disponible en: https://doi.org/10.1016/S0140-6736(15)01274-X

Villalba L, Daquarti G, Corneli M. Imágenes en amiloidosis cardiaca [Internet]. Disponible en: https://doi.org/10.32407/rcon/2020154/0090-0097

Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association [Internet]. Circulation. 2020;142(1). Disponible en: https://doi.org/10.1161/CIR.0000000000000792

Systemic immunoglobulin light chain amyloidosis. Nature Reviews Disease Primers [Internet]. Disponible en: https://doi.org/10.1038/s41572-018-0040-5

Ozga M, Zhao Q, Benson Jr. D, Elder P, Williams N, Bumma N, et al. AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival [Internet]. Cancer Medicine. 2021;10(3):965–73. Disponible en: https://doi.org/10.1002/cam4.3683

Cornell RF, Fraser R, Costa L, Goodman S, Estrada-Merly N, Lee C, et al. Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden [Internet]. Transplantation and Cellular Therapy. 2021;27(3):264.e1-264.e7. Disponible en: https://doi.org/10.1016/j.jtct.2020.11.018

Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and Colchicine. N Engl J Med. 1997;336(17):1202–7.

Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibeira MT, Kwok F, et al. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis [Internet]. Journal of Clinical Oncology. 2020;38(28):3252–60. Disponible en: https://doi.org/10.1200/JCO.20.01285

Venner CP, Lane T, Foard D, Rannigan L, Gibbs SDJ, Pinney JH, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival [Internet]. Blood. 2012;119(19):4387–90. Disponible en: https://doi.org/10.1182/blood-2011-10-388462

Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis [Internet]. Blood. 2012;119(19):4391–4. Disponible en: https://doi.org/10.1182/blood-2011-11-390930

Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis [Internet]. New England Journal of Medicine. 2021;385(1):46–58. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa2028631

Palladini G. Advances in the treatment of light chain amyloidosis: Current Opinion in Oncology [Internet]. LWW. Disponible en: https://doi.org/10.1097/CCO.0000000000000881

Staron A, Zheng L, Doros G, Connors LH, Mendelson LM, Joshi T, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study [Internet]. Blood Cancer Journal. Nature Publishing Group; 2021;11(8):1–10. Disponible en: https://doi.org/10.1038/s41408-021-00529-w

OJS System - Metabiblioteca |